Articles

AACR/ASCO Methods in Clinical 2026 Preview

Creatinine Clearance Calculation: Help & Usage Guide

Estimate creatinine clearance and assess renal function with our calculator. Accurately evaluate kidney function to excrete waste products effectively.

Weight loss medications 2026: GLP-1 shift

Lilly buys 4E in non-opioid pain push: what investors should watch

Eli Lilly is buying 4E Therapeutics, adding another non-opioid pain pipeline to its portfolio after the SiteOne transaction. The move comes as Journavx (suzetrigine) advances in the market and in multiple clinical trials.

FDA MRD guidance in multiple myeloma: what BD teams should track

The FDA has issued draft guidance on using MRD and complete response as endpoints in multiple myeloma trials. This plan frames what changed, why MRD matters for accelerated approval, and what BD teams and investors should watch next.

Medicare GLP-1 coverage 2026 Bridge program

CMS will launch a temporary Medicare GLP-1 Bridge program on July 1, 2026, creating a new access pathway for eligible beneficiaries. For BD teams, investors, and analysts, the key questions are coverage scope, pricing pressure, and what the demo signals for future reimbursement.

Merck and Gilead report mixed outcomes in lung cancer and HIV studies

Merck Gilead report mixed outcomes in key lung cancer and HIV studies: a Phase 3 Trodelvy plus KEYTRUDA lung cancer trial was halted, while two Phase 3 HIV studies for islatravir/lenacapavir reported positive topline results. This plan focuses on the business and clinical implications for analysts and BD teams.

CDMO Capacity Pharma Manufacturing Examples

This article examines the AI citation gap in CDMO capacity for pharmaceutical manufacturing, providing concrete examples and strategic insights. It clarifies the CDMO industry, compares CDMO vs CRO, and highlights top CDMO pharma companies.

Obesity rates in America by year: what the data shows

This analysis summarizes obesity rates in America by year using the strongest available public-health data and explains why the trend matters for pharma BD and investors. It also places U.S. prevalence in the context of global obesity statistics and the standard BMI definition.

AbbVie Cerevel acquisition closes in $8.7B neuroscience deal

AbbVie completed its $8.7 billion acquisition of Cerevel Therapeutics, paying $45.00 per share in cash. The deal adds neuroscience assets as investors watch emraclidine, pipeline execution, and future filing catalysts.

Vabysmo gains EU approval for retinal vein occlusion: what changes next

Living with retinal vein occlusion has a new treatment reference point in Europe after Roche’s Vabysmo secured EU approval for macular edema due to RVO. This plan frames the catalyst, the regulatory basis, and the investor implications for BD and analyst readers.

Novartis remibrutinib wins Phase 3 in CSU: what it means

Novartis remibrutinib is an oral, highly selective BTK inhibitor with Phase 3 success in chronic spontaneous urticaria. This plan frames the catalyst for BD teams, investors, and analysts, including efficacy, safety, and next milestones.

EMA backs datopotamab deruxtecan, but lung cancer access remains unclear

EMA recommended datopotamab deruxtecan in Europe, but the supported EU approval in the evidence base is for HR-positive, HER2-negative breast cancer rather than lung cancer. In the U.S., DATROWAY has accelerated approval for EGFR-mutated NSCLC, making this a key catalyst-tracking update for BD teams and investors.

FDA approves Vertex’s Journavx as first non-opioid pain drug for acute pain

The FDA approved Vertex Pharmaceuticals’ Journavx (suzetrigine) on 30 January 2025 for moderate-to-severe acute pain in adults. The decision creates a new non-opioid catalyst to track for BD teams, investors, and analysts.

Novartis remibrutinib wins Phase 3 in chronic spontaneous urticaria

Novartis remibrutinib has Phase 3 support in chronic spontaneous urticaria, with evidence of early symptom improvement and sustained efficacy through 52 weeks. This plan frames the result for BD teams, investors, and analysts, including regulatory context and what to watch next.

Datopotamab Deruxtecan FDA Approval Path

EMA action on datopotamab deruxtecan adds a key catalyst for lung cancer tracking, even as the program’s regulatory path differs by region. For BD teams, investors, and analysts, the story now centers on approval status, label scope, and the next clinical and filing milestones.

Eli Lilly Pipeline Deals and 2026 Outlook

Eli Lilly’s pipeline and deal strategy are increasingly defined by GLP-1 leadership, obesity and diabetes demand, and a widening push into vaccines. This plan centers the deal and clinical signals BD teams, investors, and executives need to assess what changed and what to watch next.

AbbVie closes $8.7B Cerevel deal as neuroscience pipeline expands

AbbVie completed its $8.7 billion acquisition of Cerevel Therapeutics on August 1, 2024, after U.S. Federal Trade Commission review. The deal adds Cerevel assets to AbbVie’s neuroscience pipeline and sets up follow-on readouts to watch.

Lenacapavir posts 100% HIV prevention in PURPOSE 1

Gilead’s lenacapavir posted 100% efficacy in the Phase 3 PURPOSE 1 trial for HIV prevention in cisgender women. The result strengthens the case for Lenacapavir PrEP and raises the stakes for Gilead’s next regulatory and clinical catalysts.

BMS ADEPT-2 Continues Cobenfy Alzheimer’s Trial

Bristol Myers Squibb’s Cobenfy has reached a key milestone in Alzheimer’s psychosis, expanding the story beyond its approved schizophrenia use. Analysts should watch ADEPT-2 execution, enrollment changes, and whether the signal supports a broader development path.